Tumor-derived exosome-based microRNA-206 delivery system as dual modulators of the immune microenvironment and gut microbiota for colorectal cancer therapy.

Immune checkpoint blockade (ICB) holds significant therapeutic potential for colorectal cancer (CRC). However, its clinical efficacy remains limited by relatively low response rates. Recent studies suggest that combining microRNAs (miRNAs) with immune checkpoint blockade offers a promising strategy for enhancing CRC treatment outcomes. In our previous work, we found that miRNA-206 (miR206), a small non-coding RNA, effectively inhibited tumor growth by targeting T cell immune receptor with immunoglobulin and ITIM domain (TIGIT). Nevertheless, how miR206 contributes to the modulation of the immune microenvironment and whether it influences gut microbiota composition remain unclear. Herein, we proposed an engineered exosome delivery system consisting of extracellular vesicles derived from miR206-overexpressing tumor cells (LV-miR206-HT29-EXO) to enhance CRC immunotherapy. The engineered exosome facilitated the efficient delivery of miR206 to tumor sites. In vitro and in vivo studies demonstrated that LV-miR206-HT29-EXO significantly inhibited tumor growth, migration, and invasion while promoting tumor apoptosis. Notably, the engineered nanoplatform also exhibited substantial antitumor efficacy in CRC mice models by modulating interactions among tumor cells, the gut microbiota, and the immune microenvironment. These findings highlighted the potential of tumor-derived exosome-based miRNA delivery system for CRC immunotherapy.